Clinical trials: Patients with Advanced Solid Tumors
Urothelial Carcinoma, Renal Cell Carcinoma
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
The objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma
- Trial name
- NCT05661955
- Testing
- BGB-A445, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 113 people
- Sponsor
- BeiGene
Solid Tumors
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
A Multicenter, Nonrandomized, Open-Label Phase I/IIClinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Solid Tumors
- Trial name
- NCT04685226
- Testing
- ICP-723
- Where
- 24 sites in China
- Volunteers
- 310 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Advanced Solid Tumors
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies
This study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of IBI389 as a single agent, and in combination with sintilimab, and (or) chemotherapy in patients with…
- Trial name
- NCT05164458
- Testing
- IBI 308 injection, IBI 389 Injection
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Glioma, Other Solid Tumours
A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours
This is a phase 1/2A, open label, non-randomized study in patients with advanced solid tumours including malignant glioma
- Trial name
- NCT01792310
- Testing
- LAM561
- Where
- 5 sites in Spain, United Kingdom
- Volunteers
- 54 people
- Sponsor
- Laminar Pharmaceuticals
Advanced Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the MTD and/or recommended Phase 2 dose (RP2D) and assess the DLT of FHND5071.
- Trial name
- NCT05818917
- Testing
- FHND5071
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
HNSCC, Melanoma
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies.
- Conditions
- HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer
- Trial name
- ACT (NCT05902520)
- Testing
- DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- AgonOx, Inc.
Breast Cancer, Ovarian Cancer
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer
- Trial name
- NCT06065059
- Testing
- TNG348, Olaparib
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Tango Therapeutics, Inc.
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors
The goal of this clinical trial is To establish the safety profile and determine the dose-limited toxicity (DLT) of PEP07 monotherapy in patients with advanced or metastatic solid tumors.
- Trial name
- NCT05983523
- Testing
- PEP07
- Where
- 3 sites in Taiwan
- Volunteers
- 54 people
- Sponsor
- PharmaEngine
Solid Tumor
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
This study was designed to evaluate the efficacy and safety of 7MW3711 in combination with JS207 in subjects with solid tumor.
- Trial name
- NCT07466160
- Testing
- 7MW3711, JS207, Cisplatin
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Solid Tumor, Advanced Cancer
Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies
The main objective of this study is to determine the maximum tolerated dose (MTD) of Oratecan in combination with capecitabine
- Trial name
- NCT01463982
- Testing
- Oratecan and Capecitabine
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Advanced Solid Tumors, Lymphoid Malignancies
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
This study assesses the tolerability, safety, efficacy and pharmacokinetics of Bardoxolone methyl (RTA 402) in advanced solid tumors and lymphoid malignancies.
- Trial name
- NCT00529438
- Testing
- Bardoxolone methyl
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Biogen
Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors.
- Trial name
- NCT07287917
- Testing
- AMXT 1501 Dicaprate, DFMO, Fulvestrant
- Where
- 20 sites in United States
- Volunteers
- 92 people
- Sponsor
- Aminex Therapeutics, Inc.
Advanced Solid Malignancies
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors
This study will study the safety, tolerability and metabolism of a drug called HSP990 when given by mouth once a week or twice weekly to subjects with advanced solid tumors.
- Trial name
- NCT00879905
- Testing
- HSP990
- Where
- 3 sites in Canada, France and 1 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors, Cancer
A Clinical Study of PA5 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if PA5 is safe and works to treat advanced solid tumors in adults. It will also learn about the tolerability and PK/PD profile of PA5.
- Trial name
- NCT07702162
- Testing
- PA5
- Where
- 2 sites in China
- Volunteers
- 49 people
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Solid Malignancies
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor
Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors.
- Trial name
- NCT00033202
- Testing
- Gimatecan® (ST-1481)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sigma-Tau Research, Inc.
Advanced CEACAM6-expressing Solid Tumors
Study of BAY1834942 in Patients With Solid Tumors
This is an open-label, Phase 1, first-in-human, dose escalation and expansion study designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and tumor response profile of the…
- Trial name
- NCT03596372
- Testing
- BAY1834942
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Bayer
Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer
A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive…
- Conditions
- Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
- Trial name
- NCT04492488
- Testing
- MRG002
- Where
- 2 sites in United States
- Volunteers
- 129 people
- Sponsor
- Shanghai Miracogen Inc.
Advanced Solid Tumors
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Surufatinib single agent or Surufatinib combined with Toripalimab in patients with advanced solid tumors.
- Trial name
- NCT04169672
- Testing
- Surufatinib, Toripalimab
- Where
- 2 sites in China
- Volunteers
- 248 people
- Sponsor
- Hutchison Medipharma Limited
Head and Neck Tumors, Solid Tumors
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors
This is an open-label, multicenter, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036 Bispecific Antibody Injection in patients with…
- Trial name
- NCT07763639
- Testing
- SI-B036
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.